Tesamorelin

Research Papers and Clinical Trials

The research on tesamorelin, a growth hormone-releasing hormone analog, spans several therapeutic areas with varying levels of evidence. Based on available studies, the research landscape shows both established applications and emerging investigational uses.

HIV-Related Applications

The strongest evidence base exists for tesamorelin's use in HIV patients. A completed pharmacokinetic and pharmacodynamic Phase 1 study (NCT02012556) examined TH9507 (tesamorelin's research designation) in HIV-positive patients, establishing basic safety and dosing parameters. A separate completed trial (NCT00795210) investigated short-term growth hormone effects in HIV-infected patients.

More recently, research has expanded to examine tesamorelin's effects on liver complications in HIV patients, with one completed study (NCT02196831) specifically examining impacts on liver fat and histology. The TRIUMPH trial protocol (2026) represents an ongoing effort to evaluate tesamorelin as an exercise adjunct for improving physical function in HIV patients, though specific study design details and sample sizes are not provided in the available evidence.

A 2026 case report highlights tesamorelin's role in managing excess visceral abdominal fat in people living with HIV, contrasting its therapeutic pathway with GLP-1 receptor agonists for different patient presentations.

Metabolic and Body Composition Studies

A completed Phase 2 trial (NCT00675506) investigated tesamorelin's effectiveness in reducing abdominal fat in obese individuals, expanding its potential beyond HIV populations. However, specific outcomes and sample sizes are not detailed in the available evidence.

Neurological Applications

Emerging research suggests potential neurological benefits. A 2026 study examined growth hormone-releasing hormone effects on cognition and brain connectivity in adults with normal cognition to mild cognitive impairment, though sample sizes and detailed results are not provided. A withdrawn Phase 2 trial (NCT02931474) had planned to investigate GHRH effects on sleep and endocrine regulation in service members with traumatic brain injury and insomnia.

Safety and Regulatory Considerations

Recent review articles (2026) have addressed tesamorelin within broader contexts of performance-enhancing peptides and injectable peptides in sports medicine, highlighting safety profiles and anti-doping implications. These reviews suggest growing clinical interest but emphasize the need for evidence-based applications.

Limitations of Current Evidence

While multiple trials are listed as completed, detailed results, sample sizes, and primary outcomes are not available in the provided evidence. The research spans from 2012 to 2026, but many recent publications appear to be reviews, protocols, or case reports rather than large-scale controlled trials, suggesting the evidence base may still be developing for newer applications beyond HIV-related uses.

Disclaimer: This synthesis is based solely on the research citations provided and does not constitute medical advice. Consult healthcare providers for treatment decisions.